Histidine-tryptophan-ketoglutarate
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| This article or section needs to be wikified to meet Wikipedia's quality standards. Please help improve this article with relevant internal links. |
Histidine-tryptophan-ketoglutarate (Custodiol® HTK) solution is a high-flow, low-potassium preservation solution used for organ transplantation. HTK solution is intended for perfusion and flushing of donor liver kidney, heart, lung and pancreas prior to removal from the donor and for preserving these organs during hypothermic storage and transport to the recipient. HTK solution is based on the principle of inactivating organ function by withdrawal of extracellular sodium and calcium, together with intensive buffering of the extracellular space by means of histidine/histidine hydrochloride, so as to prolong the period during which the organs will tolerate interruption of oxygenated blood. The composition of HTK is similar to that of extracellular fluid. All of the components of HTK occur naturally in the body.1
| Component | HTK |
|---|---|
| Sodium (mmol/L) | 15 |
| Potassium (mmol/L) | 10 |
| Magnesium (mmol/L) | 4 |
| Calcium (mmol/L) | 0.015 |
| Ketoglutarate/glutamic acid (mmol/L) | 1 |
| Histidine (mmol/L) | 198 |
| Mannitol (mmol/L) | 30 |
| Tryptophan (mmol/L) | 2 |
| Osmolarity (mOsm/L) | 310 |
Custodiol® HTK is the registered trademark of Dr. Franz Köhler (Chemie GmbH, Germany).
References
1. 510(k) Summary. Custodiol® HTK Solution Common/Classification Name: Isolated Kidney Perfusion and Transport System and Accessories, 21 CFR 876.5880; Franz Kohler. Prepared December 14, 2004. http://www.fda.gov/cdrh/pdf4/K043461.pdf
2. Ringe B.,et al. Safety and efficacy of living donor liver preservation with HTK solution. Transplant Proc. 2005;37:316–319.
3. Agarawal A., et al. Follow-up experience using histidine-tryptophan-ketoglutarate solution in clinical pancreas transplantation Transplant Proc. 2005;37:3523–3526.
4. Pokorny H., et al.: Histidine-tryptophan-ketoglutarate solution for organ preservation in human liver transplantation — a prospective multi-centre observation study. Transpl Int. 2004;17:256-60.
5. de Boer J., et al.: Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins. Transpl lnt. 1999;12:447-453.
6. Hesse U.J., et al.: Organ preservation with HTK and UW solution. Pabst Sci. Publishers, D-49525 Lengerich, 1999.
7. Hatano E., et al: Hepatic preservation with histidine-tryptophan-ketoglutarate solution in living related and cadaveric liver transplantation. Clin Sci. 1997;93:81-88.
External links
www.custodiol.ca
www.custodiol.com
Dr. Franz Köhler Chemie GmbH
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
